Klaus
Elenius
Professor, Institute of Biomedicine
Director, BioCity Turku
Turku Bioscience Centre
MD, PhD, professor
Research
ACTIONABLE RECEPTOR TYROSINE KINASE SIGNALING
Our goal is to understand how receptor tyrosine kinases (RTK) regulate the pathogenesis of human diseases, such as cancer. This information is needed for the development of molecularly targeted therapies. To recognize aberrations of RTK signaling in diseased tissue our laboratory also works on the molecular mechanism by which RTKs control normal processes, such as embryonic development. The work mainly focuses on the ErbB family of RTKs. Our laboratory has contributed to the field by e.g. by characterizing novel RTK signaling mechanisms, by identifying novel ErbB4 isoforms, and by determining the role of ErbBs and their ligands in angiogenesis.
Current topics
- Screens for predictive RTK mutations
- Novel RTK signaling mechanisms
- Development of preclinical models for development novel RTK inhibitors
- Sequencing of RTK inhibitor drug administration with cytotoxic agents
- In vitro “basket trials” with ErbB inhibitor drugs
- RTK signaling in angiogenesis and cardiovascular diseases
- RTKs in pediatric malignancies
- Biological role of novel ErbB4 isoforms in diseases and development
Elenius Lab members
- Anne Jokilammi, PhD
- Elli Narvi, PhD
- Deepankar Chakroborty, MSc
- Juho Heliste, MD
- Marika Koivu, MSc
- Johannes Merilahti, MSc
- Veera Ojala, MSc
- Janne Nordberg, MD
- Fred Saarinen, MSc
- Katri Vaparanta, MSc
- Kaisa Aalto, BM
- Maria Helkkula, BM
- Matias Mäenpää, BM
- Peppi Kirjalainen, BM
- Jori Torkkila, BM
Publications
INTERACTION BETWEEN MARROW-DERIVED HUMAN MESENCHYMAL STEM CELLS AND PERIPHERAL BLOOD MONONUCLEAR CELLS IN ENDOTHELIAL CELL DIFFERENTIATION (2011)
Scandinavian Journal of Surgery
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Function of ERBB4 is determined by alternative splicing. (2011)
Cell Cycle
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
ErbB targeted drugs and angiogenesis (2010)
Current Vascular Pharmacology
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Retention of prolyl hydroxylase PHD2 in the cytoplasm prevents PHD2-induced anchorage-independent carcinoma cell growth (2010)
Experimental Cell Research
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Potential of ErbB4 antibodies for cancer therapy (2010)
Future Oncology
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Cell Death or Survival Promoted by Alternative Isoforms of ErbB4 (2010)
Molecular Biology of the Cell
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma (2010)
Expert Opinion on Emerging Drugs
(Vertaisarvioitu katsausartikkeli tieteellisessä aikakauslehdessä (A2))
Removal of cell surface heparan sulfate increases TACE activity and cleavage of ErbB4 receptor (2009)
BMC Cell Biology
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Suppression of breast cancer growth by a monoclonal antibody specifically targeting cleavable ErbB4 isoforms. (2009)
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))Pim-1 Kinase Expression Predicts Radiation Response in Squamocellular Carcinoma of Head and Neck and Is under the Control of Epidermal Growth Factor Receptor (2009)
Neoplasia : An International Journal for Oncology Research
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))